PublisherBMJ Publishing Group
MetadataShow full item record
DescriptionDrawing on their experience in producing a Cochrane review of neuraminidase inhibitors for influenza, the authors discuss how to improve the reliability of systematic reviews
CitationJefferson, T., Doshi, P., Thompson, M., Heneghan, C. (2011). Ensuring safe and effective drugs: who can do what it takes? BMJ, 342. DOI: 10.1136/bmj.c7258
Keywordclinical study reports
F. Hoffman-La Roche & Co.
Access to Information--legislation & jurisprudence
Clinical Trials as Topic
Review Literature as Topic
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/6616
- Neuraminidase inhibitors--the story behind the Cochrane review.
- Authors: Doshi P
- Issue date: 2009 Dec 8
- The truth about Tamiflu? Neuraminidase inhibitors in pandemic A/H1N1 flu.
- Authors: Weber JT, Nicoll A, Bridges CB, Ciancio BC
- Issue date: 2010 Jan 13
- Oseltamivir resistance: what does it mean clinically?
- Authors: Baum SG
- Issue date: 2009 Dec 15
- Global transmission of oseltamivir-resistant influenza.
- Authors: Moscona A
- Issue date: 2009 Mar 5
- Neuraminidase inhibitors were widely used in the UK during the 2009 influenza A(H1N1) pandemic.
- Authors: Nguyen-Van-Tam JS, Nicholson KG
- Issue date: 2011 Feb